circulation 2011 dec 124(24) e783 831, figures
TRANSCRIPT
![Page 1: Circulation 2011 dec 124(24) e783 831, figures](https://reader035.vdocuments.us/reader035/viewer/2022062820/58a7b47c1a28ab70368b567f/html5/thumbnails/1.jpg)
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
by , Bernard J. Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski, Christine E. Seidman, Jeffrey A. Towbin, James E. Udelson, and Clyde
W. Yancy
CirculationVolume 124(24):e783-e831
December 13, 2011
Copyright © American Heart Association, Inc. All rights reserved.
![Page 2: Circulation 2011 dec 124(24) e783 831, figures](https://reader035.vdocuments.us/reader035/viewer/2022062820/58a7b47c1a28ab70368b567f/html5/thumbnails/2.jpg)
Applying Classification of Recommendation and Level of Evidence.
Writing Committee Members et al. Circulation. 2011;124:e783-e831
Copyright © American Heart Association, Inc. All rights reserved.
![Page 3: Circulation 2011 dec 124(24) e783 831, figures](https://reader035.vdocuments.us/reader035/viewer/2022062820/58a7b47c1a28ab70368b567f/html5/thumbnails/3.jpg)
Summary of the nomenclature that distinguishes HCM from other genetic diseases associated with LV hypertrophy. *At this time the overwhelming evidence links the clinical diagnosis of HCM
with a variety of genes encoding protein components of the cardiac sarcomere.
Writing Committee Members et al. Circulation. 2011;124:e783-e831
Copyright © American Heart Association, Inc. All rights reserved.
![Page 4: Circulation 2011 dec 124(24) e783 831, figures](https://reader035.vdocuments.us/reader035/viewer/2022062820/58a7b47c1a28ab70368b567f/html5/thumbnails/4.jpg)
Prognosis profiles for HCM and targets for therapy.
Writing Committee Members et al. Circulation. 2011;124:e783-e831
Copyright © American Heart Association, Inc. All rights reserved.
![Page 5: Circulation 2011 dec 124(24) e783 831, figures](https://reader035.vdocuments.us/reader035/viewer/2022062820/58a7b47c1a28ab70368b567f/html5/thumbnails/5.jpg)
Treatment algorithm.
Writing Committee Members et al. Circulation. 2011;124:e783-e831
Copyright © American Heart Association, Inc. All rights reserved.
![Page 6: Circulation 2011 dec 124(24) e783 831, figures](https://reader035.vdocuments.us/reader035/viewer/2022062820/58a7b47c1a28ab70368b567f/html5/thumbnails/6.jpg)
Indications for ICDs in HCM. *SCD risk modifiers include established risk factors and emerging risk modifiers (Section 6.3.1.2).
Writing Committee Members et al. Circulation. 2011;124:e783-e831
Copyright © American Heart Association, Inc. All rights reserved.
![Page 7: Circulation 2011 dec 124(24) e783 831, figures](https://reader035.vdocuments.us/reader035/viewer/2022062820/58a7b47c1a28ab70368b567f/html5/thumbnails/7.jpg)
Management of AF in HCM. AF indicates atrial fibrillation; AV, atrioventricular; INR, international normalized ratio; PPM, permanent pacemaker; and PVI, pulmonary vein isolation.
Writing Committee Members et al. Circulation. 2011;124:e783-e831
Copyright © American Heart Association, Inc. All rights reserved.